General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

CR governance

Corporate responsibility (CR) is endorsed and ingrained at the highest level in our company. It is central to how we run our business.

Because of the importance of corporate responsibility for Novartis and our stakeholders, we recently made some changes to how it is governed and managed.

The Board of Directors approved the expansion of the mandate of the former Corporate Governance and Nomination Committee to include Corporate Responsibility, effective January 1, 2014. The new “Governance, Nomination and Corporate Responsibility Committee” will oversee our company’s strategy and governance on corporate responsibility and key issues related to corporate responsibility that may affect the Company’s business and reputation.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources, took on the role of Global Head of Corporate Responsibility effective February 26, 2014. Juergen is fully dedicated to supporting our companywide CR efforts and better coordinating our many ongoing activities.

Our CR efforts will continue to be driven by a team of senior leaders that has a special role in holding the company accountable for delivering on our commitments. Led by Juergen Brokatzky-Geiger, the Corporate Responsibility Steering Committee (CRSC) meets bi-monthly to monitor our progress on meeting corporate responsibility targets. They are charged with continually assessing whether we are creating and seizing the right opportunities to realize our commitment to improving health. Each Novartis division has a seat at the table. The CRSC is ultimately responsible for shaping the company’s strategy and performance measurements for corporate responsibility and making recommendations to the ECN.

Our company’s shared commitment to CR rests with every Novartis associate. Across Novartis, we aim for transparent reporting of annual targets and long-term objectives, as well as to incentivize management and associates to create sustainable value for Novartis in all areas of our business, including corporate responsibility.